-
Sugemalimab Receives I, A Recommendation in ESMO Guideline for Consolidation Therapy in Patients with Stage III NSCLC
Ewopharma is pleased to report that sugemalimab, licensed from partner CStone Pharmaceuticals, has received a I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline. This recommendation supports sugemalimab for consolidation therapy in patients with unresectable Stage III non-small cell lung cancer (NSCLC), who have not progressed after concurrent or sequential chemoradiotherapy. ESMO’s recommendation is expected to significantly facilitate market access for sugemalimab in the European Union and other regions, thus expanding patient reach and offering further treatment options. In February 2025, ESMO included sugemalimab in combination with chemotherapy in its guidelines with a I, A rating for the first-line…
-
Sugemalimab Achieves New Regulatory Milestone: European Commission Approves Stage Ⅲ NSCLC Indication
Ewopharma is pleased to report an important new regulatory milestone for sugemalimab licensed from Chinese partner CStone Pharmaceuticals. In late November 2025, the European Commission (EC) granted approval for a new indication for sugemalimab as monotherapy for adult patients with unresectable stage III non-small cell lung cancer (NSCLC). This applies to patients whose tumours express PD-L1 on ≥1% of tumour cells and who do not carry EGFRsensitising genetic mutations, or ALK, or ROS1 genomic aberrations, and whose disease has not progressed following platinum-based chemoradiotherapy (CRT). The EC had already approved the use of sugemalimab in combination with chemotherapy for the treatment of metastatic (Stage IV) NSCLC in July 2024. Reto…
-
Ewopharma AG Announces Exclusive Distribution Agreement for Cardiovascular Solutions in Bulgaria
Effective June 1, 2024, Ewopharma AG has the exclusive licence to distribute Translumina’s drug-eluting stents (DES) and Blue Medical’s drug-coated balloon (DCB) technologies in Bulgaria. The agreement includes two key categories of interventional cardiovascular solutions: Drug-Eluting Stents – The DES category includes biodegradable polymer and polymer-free drug-eluting stents incorporating proprietary coatings and drug formulations to reduce restenosis and improve safety. Drug-Coated Balloons – DCB treatment is based on a leave-nothing-behind concept, which ensures homogenous and immediate drug delivery to the vessel wall without the use of a polymer thus eliminating the presence of residual foreign material in the vessel. “We are proud to expand our portfolio with Translumina’s cardiovascular solutions…
-
AllergyCare AG Becomes Part Of Ewopharma Group
Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of AllergyCare AG, a Swiss distribution company of pharmaceutical and consumer health products with a focus on the prevention and treatment of allergies. As part of a succession solution, the Ewopharma Group was able to acquire AllergyCare AG retroactively from 1st January 2024. Ewopharma and AllergyCare AG enjoyed several specific points of contact through the same brand they represent. For the last decades, Ewopharma Group has successfully grown its business and continued its geographic expansion. The acquisition opens new expertise for Ewopharma to explore the Swiss home market, this…
-
Ewopharma and CStone enter into a Strategic Partnership for Sugemalimab in Central Eastern Europe and Switzerland
Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovationdriven biopharmaceutical company focused on the research and development of anti-cancer therapies. Under the agreement, Ewopharma will gain the commercial rights for sugemalimab in Switzerland and 18 Central Eastern European countries (CEE). These include EU member countries Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, and Slovenia, as well as non- EU countries Albania, Bosnia & Herzegovina, Kosovo, North Macedonia, Moldova, Montenegro, Serbia. The partnership will maximize the value of sugemalimab (anti-PD-L1 monoclonal antibody) in Central Eastern Europe and Switzerland. CStone will receive up to $51.3 million in…
-
Neomed s.r.o. becomes part of Ewopharma Group
Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of Neomed s.r.o., a Czech Distribution company of pharmaceuticals, medical devices, and cosmetics. As part of a succession solution, the Ewopharma Group was able to acquire Neomed s.r.o. as of 1 June 2023. In the past, Ewopharma and Neomed enjoyed several specific, successful collaborations in the region. Over the past years, Ewopharma has successfully grown the business and continued to expand geographically. The acquisition opens new expertise for Ewopharma, this with Neomed’s existing staff and partnerships. Mr. Alain Staub, CEO of the Ewopharma Group, commented “This is an important…
